Activation of endogenous immune responses by immune checkpoint blockade (ICB) has revolutionized cancer therapy and has become standard of care for several cancer types. However, many patients do not respond to ICB or other forms of immunotherapy or develop resistance over time. Therefore, a better understanding of the interactions within the tumor microenvironment (TME) is required to develop patient-tailored treatments that unleash an effective anti-tumor response. This LabLinks will bring together basic, translational and clinical scientists who study different components of the TME, in order to foster connections and bridge the gap between the bench and bedside.
This event is free to attend, though space is limited. Register today to join us in Amsterdam for this in-person event!